What can circulating tumor DNA reveal about treatment response?
The KEYNOTE-905 conversation continues at #ESMO2026.
Following his presentation, Jon Chatzkel joined Brian and Tom to explore ctDNA kinetics from the trial and what these findings may tell us about the biological response to neoadjuvant treatment in muscle-invasive bladder cancer.
🎙️ Episode 523 of The Uromigos Podcast is now live: https://apple.co/47AYGMk
#Uromigos #BladderCancer #ctDNA #GUOncology
356 浏览 · 8 赞 · 6 转发 · 0 回复
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：Uromigos · x.com